Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

The value of your shares will be the same price as management's as their's go up. I don't understand your question and it really doesn't bother me that management gave themselves a raise. Remember, this is the same management that supported the company financially for years. I don't begrudge them having a lot of shares for their efforts. I hope they make a ton of money since I'm along for the ride and will benefit greatly as their share value increases.

The stock has been in a sideways trading range for a year now. This is a biotech company. Nothing happens quickly. Look at the chart for the past three years. It is up overall.

The focus really needs to be on what happens to the company now.

We have two trials listed on NIH's Clinical Trials page and I'm expecting two more this year for a total of four. Management has been actively working on moving this company forward where it counts:
http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search

Look at page 28 of the 10Q for Prurisol. This IND will be filed soon:
http://www.sec.gov/Archives/edgar/data/1355250/000147793214000589/ctix_10q.htm

Prurisol is our anti-psoriasis drug candidate. It is a small molecule with a molecular weight of less than 500 MW. It is synthesized through a multi-step process using commercially available starting materials. Prurisol acts through immune modulation and PRINS reduction.

In January 2014, the Company submitted an application to the Institutional Review Board ("IRB") responsible for the planned clinical study of the Company's psoriasis drug Prurisol at a Florida phase 1 unit. The phase 1 trial is a short crossover study being conducted at the request of the U.S. Food and Drug Administration ("FDA") with the purpose of demonstrating that Prurisol, an ester of abacavir, converts into abacavir in humans, just as it did in animal models. Once IRB approval is received, Cellceutix will file an Investigational New Drug application with the FDA. The trial is expected to take approximately one and a half months to complete, at which time the Company will move forward with initiation of a larger Phase 2/3 trial under the guidance from the FDA that a 505(b)(2) designation is an appropriate developmental pathway for Prurisol.

The kevetrin trial is moving along and we'll get results from that this year. The longer the trial goes, the more comfortable I am with that one.

The following post lays out possible outcomes on the Brilacidin trial showing it isn't a binary event. http://investorshub.advfn.com/boards/read_msg.aspx?message_id=96757714

Many wait on the sidelines until trial results come in and that is the safest way to play biotech. You pay much more for that safety. Everyone has a different style of trading and/or investing. All are valid. Good luck in your choice. ;)

Where we came from: